The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]
  • No CSPEC related information was provided by the message!

  • See Evidence submitted by expert panel for details.

Variant: NM_000540.3(RYR1):c.14477C>T (p.Thr4826Ile)

CA024154

12978 (ClinVar)

Gene: RYR1
Condition: malignant hyperthermia, susceptibility to, 1
Inheritance Mode: Autosomal dominant inheritance
UUID: ef1c927e-3971-4640-8125-a82897971b0c
Approved on: 2021-03-22
Published on: 2022-07-11

HGVS expressions

NM_000540.3:c.14477C>T
NM_000540.3(RYR1):c.14477C>T (p.Thr4826Ile)
NC_000019.10:g.38580094C>T
CM000681.2:g.38580094C>T
NC_000019.9:g.39070734C>T
CM000681.1:g.39070734C>T
NC_000019.8:g.43762574C>T
NG_008866.1:g.151395C>T
ENST00000593677.2:n.1413C>T
ENST00000688602.1:n.2810C>T
ENST00000689936.1:n.2782C>T
ENST00000359596.8:c.14477C>T
ENST00000355481.8:c.14462C>T
ENST00000359596.7:n.14477C>T
ENST00000360985.7:c.14459C>T
NM_000540.2:c.14477C>T
NM_001042723.1:c.14462C>T
NM_001042723.2:c.14462C>T

Pathogenic

Met criteria codes 5
PM1_Supporting PP3_Moderate PP1_Strong PS3 PS4
Not Met criteria codes 2
BS1 BA1

Evidence Links 0

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Malignant Hyperthermia Susceptibility VCEP
This pathogenicity assessment is relevant only for malignant hyperthermia susceptibility (MHS) inherited in an autosomal dominant pattern. Variants in RYR1 can also cause other myopathies inherited in an autosomal dominant pattern or in an autosomal recessive pattern. Some of these disorders may predispose individuals to malignant hyperthermia. RYR1 variants may also contribute to a malignant hyperthermia reaction in combination with other genetic and non-genetic factors and the clinician needs to consider such factors in making management decisions. This sequence variant predicts a substitution of threonine with isoleucine at codon 4826 of the RYR1 protein, p.(Thr4826Ile). The maximum allele frequency for this variant among the six major gnomAD populations is NFE: 0.000009, a frequency consistent with pathogenicity for MHS. This variant has been reported in 14 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID: 30236257, 10888602, 16163667, 18564801, 25960145). This variant segregates with MHS in seven families, PP1_Strong ( PMID: 30236257). Two studies using a knock-in mouse model support pathogenicity of this variant. One study demonstrated a malignant hyperthermia reaction in response to agonist (PMID: 22131268). The other ex vivo study showed increased response to agonist with increased calcium release (PMID: 22139840), PS3_Strong. Studies in dyspedic myotubes also show increased sensitivity to RYR1 agonists (PMID: 12732639, 15347586). This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1_Sup (PMID: 21118704). A REVEL score >0.85 (0.977) supports a pathogenic status for this variant, PP3_Moderate. This variant has been classified as Pathogenic. Criteria implemented: PS3, PS4, PM1_Supporting, PP1_Strong, PP3_Moderate.
Met criteria codes
PM1_Supporting
This variant resides in a region of RYR1 considered to be a hotspot for pathogenic variants that contribute to MHS, PM1_Sup (PMID: 21118704).
PP3_Moderate
A REVEL score >0.85 (0.977) supports a pathogenic status for this variant, PP3_Moderate.
PP1_Strong
This variant segregates with MHS in seven families, PP1_Strong ( PMID: 30236257).
PS3
Two studies using a knock-in mouse model support pathogenicity of this variant. One study demonstrated a malignant hyperthermia reaction in response to agonist (PMID: 22131268). The other ex vivo study showed increased response to agonist with increased calcium release (PMID: 22139840), PS3_Strong. Studies in dyspedic myotubes also show increased sensitivity to RYR1 agonists (PMID: 12732639, 15347586).
PS4
This variant has been reported in 14 unrelated individuals who have a personal or family history of a malignant hyperthermia reaction, all of these individuals had a positive in vitro contracture test (IVCT) or caffeine halothane contracture test (CHCT) result (if the proband was unavailable for testing, a positive diagnostic test result in a mutation-positive relative was counted), PS4 (PMID: 30236257, 10888602, 16163667, 18564801, 25960145).
Not Met criteria codes
BS1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
BA1
No code specific comments provided, please refer to the summary above or general recommendations provided in the guideline
The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.